Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
State Street Corporation reports beneficial ownership of 2,804,168 shares (4.2%) of CELLDex Therapeutics common stock. The filing shows shared voting power of 2,620,053 shares and shared dispositive power over 2,804,168 shares. The Schedule 13G lists affiliated investment adviser entities as holders.
Insights
Large passive holder disclosure: confirms State Street's passive beneficial stake.
State Street Corporation reports beneficial ownership of 2,804,168 shares, representing 4.2% of the class, with shared voting power of 2,620,053. The filing lists several affiliated investment adviser entities (IA) as the reporting subsidiaries.
Because this is a Schedule 13G disclosure, it reflects passive ownership reporting rules. The cash‑flow treatment and any plans to trade are not stated in the excerpt; future filings would show changes in position.
Key Figures
Beneficial ownership:2,804,168 sharesPercent of class:4.2%Shared voting power:2,620,053 shares+3 more
6 metrics
Beneficial ownership2,804,168 sharesAmount beneficially owned as reported in Schedule 13G
Percent of class4.2%Percent of common stock beneficially owned
Shared voting power2,620,053 sharesShared power to vote or direct the vote
Shared dispositive power2,804,168 sharesShared power to dispose or direct the disposition
"Item 1. | (a) | Name of issuer: CELLDex Therapeutics Inc"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Shared dispositive powerregulatory
"(iv) Shared power to dispose or to direct the disposition of: 2,804,168"
Investment Adviser (IA)financial
"SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA)"
An investment adviser (IA) is a person or firm that provides personalized guidance on buying, selling, or holding investments and often manages client portfolios for a fee. Investors should care because an IA has a legal duty to act in the client's best interest—think of them as a navigator who plans and steers your financial journey—so their advice, fee structure and potential conflicts can directly affect returns and financial risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does State Street (CLDX) report in CELLDex Therapeutics?
State Street reports beneficial ownership of 2,804,168 shares, equal to 4.2% of CELLDex Therapeutics' common stock. The filing shows shared voting power of 2,620,053 and shared dispositive power of 2,804,168.
Does the Schedule 13G show State Street as an active or passive holder of CLDX?
The use of a Schedule 13G indicates passive beneficial ownership reporting. The filing lists affiliated investment adviser entities, consistent with passive institutional ownership rather than an activist position.
Which State Street entities are identified in the CLDX filing?
The filing names affiliated entities including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and others, each marked with (IA) indicating investment adviser status in the excerpt.
Who signed the Schedule 13G for State Street in this filing?
The Schedule 13G is signed by Elizabeth Schaefer, listed as Senior Vice President, Chief Accounting Officer, with a signature date of 05/12/2026 in the excerpt.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
CELLDEX THERAPEUTICS INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
15117B202
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
15117B202
1
Names of Reporting Persons
STATE STREET CORPORATION
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
MASSACHUSETTS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,620,053.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,804,168.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,804,168.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.2 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
CELLDEX THERAPEUTICS INC
(b)
Address of issuer's principal executive offices:
PERRYVILLE III BUILDING 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NEW JERSEY, 08827
Item 2.
(a)
Name of person filing:
STATE STREET CORPORATION;
(b)
Address or principal business office or, if none, residence:
ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
(c)
Citizenship:
MA
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP Number(s):
15117B202
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
2804168.00
(b)
Percent of class:
4.2 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
2,620,053
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
2,804,168
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
NOT APPLICABLE
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
NOT APPLICABLE
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
NOT APPLICABLE
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
